PE20160155A1 - Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos - Google Patents

Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos

Info

Publication number
PE20160155A1
PE20160155A1 PE2015002430A PE2015002430A PE20160155A1 PE 20160155 A1 PE20160155 A1 PE 20160155A1 PE 2015002430 A PE2015002430 A PE 2015002430A PE 2015002430 A PE2015002430 A PE 2015002430A PE 20160155 A1 PE20160155 A1 PE 20160155A1
Authority
PE
Peru
Prior art keywords
preferentially
laba
compositions
salt
glycopyronium
Prior art date
Application number
PE2015002430A
Other languages
English (en)
Inventor
Colin Reisner
Sarvajna Kumar Dwivedi
David Lechuga-Ballesteros
Patrick Fitzgerald Darken
Vidya B Joshi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of PE20160155A1 publication Critical patent/PE20160155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPOSIONES FARMACEUTICAS EN SUSPENSION QUE COMPRENDE UNA COMBINACION FIJA DE AL MENOS TRES INGREDIENTES ACTIVOS: UN ANTAGONISTA MUSCARINICO DE ACCION PROLONGADA (LAMA), UN AGONISTA BETA-2 ADRENERGICO DE ACCION PROLONGADA (LABA) Y UN CORTICOSTEROIDE INHALABLE (ICS). DICHAS COMPOSICIONES PUEDEN FORMULARSE PARA EL SUMINISTRO POR VIA RESPIRATORIA A TRAVES DE UN INHALADOR DE DOSIS MEDIDA (MDI). EL AGENTE ACTIVO LABA SE SELECCIONA ENTRE BAMBUTEROL, CLENBUTEROL, FORMOTEROL, SALMETEROL, CARMOTEROL O MILVETEROL, ENTRE OTROS; PREFERENTEMENTE UNA SAL DE FORMOTEROL Y MAS PREFERENTEMENTE, FUMARATO DE FORMOTEROL. EL AGENTE ACTIVO LAMA SE SELECCIONA ENTRE GLICOPIRRONIO, DEXIPIRRONIO, ESCOPOLAMINA, DIMENHIDRINATO, TIOTROPIO, IPATROPIO, ATROPINA, ENTRE OTROS; PREFERENTEMENTE UNA SAL DE GLICOPIRRONIO Y MAS PREFERENTEMENTE, BROMURO DE GLICOPIRRONIO. EL AGENTE ACTIVO ICS SE SELECCIONA ENTRE BECLOMETASONA, BUDESONIDA, FLUTICASONA, MOMETASONA, PREDNISONA, TRIAMCINOLONA, ENTRE OTROS; PREFERENTEMENTE UNA SAL O ESTER DE MOMETASONA O BUDESONIDA. TAMBIEN SE REFIERE A METODOS PARA LA PREPARACION DE DICHAS COMPOSICIONES FARMACEUTICAS
PE2015002430A 2013-05-22 2014-05-22 Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos PE20160155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22

Publications (1)

Publication Number Publication Date
PE20160155A1 true PE20160155A1 (es) 2016-04-01

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002430A PE20160155A1 (es) 2013-05-22 2014-05-22 Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos

Country Status (20)

Country Link
US (1) US20150150787A1 (es)
EP (1) EP2999460A1 (es)
JP (1) JP2016519160A (es)
KR (1) KR20160013134A (es)
CN (1) CN105392471A (es)
AU (1) AU2014268482A1 (es)
BR (1) BR112015028964A2 (es)
CA (1) CA2912927A1 (es)
CL (1) CL2015003422A1 (es)
CR (1) CR20150645A (es)
DO (1) DOP2015000284A (es)
HK (2) HK1221653A1 (es)
MX (1) MX2015016058A (es)
NI (1) NI201500163A (es)
PE (1) PE20160155A1 (es)
PH (1) PH12015502593A1 (es)
RU (1) RU2015154720A (es)
SG (1) SG11201509543YA (es)
WO (1) WO2014190204A1 (es)
ZA (1) ZA201509016B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
MX351993B (es) * 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
JP6397025B2 (ja) * 2013-11-22 2018-09-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 吸引可能薬剤
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US20220000881A1 (en) * 2018-10-31 2022-01-06 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
IL309888A (en) * 2021-07-09 2024-03-01 Astrazeneca Pharmaceuticals Lp Aerosol drug delivery compounds, methods and systems
WO2023119093A1 (en) * 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DE69634246T2 (de) 1995-04-14 2006-01-12 Nektar Therapeutics, San Carlos Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
PT1666028E (pt) 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade
JP2007500234A (ja) 2003-05-28 2007-01-11 ネクター セラピューティクス 水に不溶な活性剤を含む医薬的成形
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2763939A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
CA2827045A1 (en) * 2011-02-17 2012-08-23 Cipla Limited Compositions of glycopyrrolate and a beta2-agonist
EP2709447A4 (en) * 2011-05-17 2014-10-22 Pearl Therapeutics Inc COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF AT LEAST TWO ACTIVE AGENTS

Also Published As

Publication number Publication date
ZA201509016B (en) 2018-07-25
KR20160013134A (ko) 2016-02-03
CA2912927A1 (en) 2014-11-27
MX2015016058A (es) 2016-12-20
SG11201509543YA (en) 2015-12-30
RU2015154720A (ru) 2017-06-27
HK1221653A1 (zh) 2017-06-09
CL2015003422A1 (es) 2016-09-02
PH12015502593A1 (en) 2016-02-29
AU2014268482A1 (en) 2016-01-07
BR112015028964A2 (pt) 2017-07-25
WO2014190204A1 (en) 2014-11-27
DOP2015000284A (es) 2016-04-29
JP2016519160A (ja) 2016-06-30
CR20150645A (es) 2016-02-10
EP2999460A1 (en) 2016-03-30
US20150150787A1 (en) 2015-06-04
NI201500163A (es) 2016-01-06
CN105392471A (zh) 2016-03-09
HK1221654A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
AR081540A1 (es) Proceso para proveer particulas con cargas electroestaticas reducidas
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
PE20091672A1 (es) Nueva dosificacion y formulacion
HRP20201711T1 (hr) Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida
HRP20180944T1 (hr) Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
CO6290637A2 (es) Composicion farmaceutica que comprende aclidinio en forma de un polvo seco de una sal farmaceuticamente aceptable mezclado con un vehiculode polvo seco farmaceuticamente aceptable
AR080747A1 (es) Proceso para preparar particulas de vehiculo para polvos secos para inhalacion
AR098982A1 (es) Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
HRP20231729T1 (hr) Kombinirana terapija za kopb
HRP20200537T1 (hr) Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
JP2019528316A5 (es)
UY35199A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos M3
NZ600789A (en) Aerosol formulation for copd
AR106687A1 (es) PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CL2016002848A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
JP2015522025A5 (es)
AR088273A1 (es) Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
JP2014527056A5 (es)
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas

Legal Events

Date Code Title Description
FD Application declared void or lapsed